Abstract

This clinical research proposal submission has as its purpose the conduct of multidisciplinary developmental therapeutic clinical trials in investigative cancer medicine with the Eastern Cooperative Oncology Group (ECOG). Rush-Presbyterian-St. Luke's Medical Center (RPSLMC) will be the primary site for this program. The Principal Investigator at the primary site and at the RPSLMC affiliated institutions will coordinate phase II and phase III clinical investigations of treatment for patients with malignant disease. The emphasis will be on multimodality studies and on facilitating collaborative clinical studies involving the RPSLMC Division of Hematology/Oncology and its Departments of Surgery and Radiation Oncology.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA025988-16
Application #
2087447
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1979-06-01
Project End
1999-04-30
Budget Start
1994-08-16
Budget End
1995-04-30
Support Year
16
Fiscal Year
1994
Total Cost
Indirect Cost

  Institution

Name
Rush University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Chicago
State
IL
Country
United States
Zip Code
60612

  Publications

Jhawer, Minaxi; Mani, Sridhar; Lefkopoulou, Myrto et al. (2006) Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: An eastern cooperative oncology group study E7282. Invest New Drugs 24:447-54
Pandya, Kishan J; Lefkopoulou, Myrto; Petrelli, Nicholas J et al. (2004) Phase II study of cisplatin and 5-fluorouracil (PF) and mitomycin C, vincristine, cisplatin and 5-fluorouracil (MVPF) in patients with metastatic large bowel cancer: an Eastern Cooperative Oncology Group study (EST 1285). Oncology 66:118-25
Ettinger, David S; Finkelstein, Dianne M; Ritch, Paul S et al. (2002) Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group randomized study (E1588). Lung Cancer 37:311-8
Witte, R S; Cnaan, A; Mansour, E G et al. (2001) Comparison of 5-fluorouracil alone, 5-fluorouracil with levamisole, and 5-fluorouracil with hepatic irradiation in the treatment of patients with residual, nonmeasurable, intra-abdominal metastasis after undergoing resection for colorectal carcinoma. Cancer 91:1020-8
Harris, J E; Ryan, L; Hoover Jr, H C et al. (2000) Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol 18:148-57
Bonomi, P; Kim, K; Fairclough, D et al. (2000) Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18:623-31
Kucuk, O; Shevrin, D H; Pandya, K J et al. (2000) Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586). Am J Clin Oncol 23:371-5
Hochster, H; Strawderman, M H; Harris, J E et al. (1999) Conventional dose melphalan is inactive in metastatic melanoma: results of an Eastern Cooperative Oncology Group Study (E1687). Anticancer Drugs 10:245-8
Rowinsky, E K; Jiroutek, M; Bonomi, P et al. (1999) Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin. Clin Cancer Res 5:767-74
Chang, A Y; Putt, M; Pandya, K J et al. (1998) Induction chemotherapy of dibromodulcitol, Adriamycin, vincristine, tamoxifen, and Halotestin with methotrexate in metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1181). Am J Clin Oncol 21:99-104

Showing the most recent 10 out of 25 publications